Table 1.
Study characteristics*
| Characteristics | No. (%) |
|---|---|
| Study characteristics | |
| Data source | |
| Other | 17 (38) |
| MEPS | 10 (22) |
| SEER or SEER-Medicare | 7 (16) |
| Academic Cancer Institute | 5 (11) |
| MarketScan | 3 (7) |
| NHIS | 3 (7) |
| Geographic setting | |
| National | 21 (47) |
| Multiple cities and/or states | 13 (29) |
| Single institute/single city | 9 (20) |
| Single state | 2 (4) |
| Service type | |
| Outpatient | 26 (58) |
| Inpatient | 20 (44) |
| Pharmacy | 19 (42) |
| Not listed/NA | 16 (36) |
| Other | 12 (27) |
| Payer type | |
| Private insurance | 29 (64) |
| Medicare | 27 (60) |
| Medicaid | 23 (51) |
| Out of pocket | 22 (49) |
| Uninsured | 19 (42) |
| Other | 16 (36) |
| Not listed | 7 (16) |
| Military/VA | 4 (9) |
| Study design | |
| Cross-sectional | 29 (64) |
| Cohort | 13 (29) |
| Based on randomized controlled trial | 3 (7) |
| Phase of cancer care | |
| Initial treatment of incident disease | 26 (58) |
| Surveillance, continuing, or monitoring | 10 (22) |
| Last year of life | 2 (4) |
| Other | 0 (0) |
| Comparison group | |
| No comparison group | 21 (47) |
| Non cancer controls | 17 (38) |
| Other comparison group | 7 (16) |
| Cancer patient characteristics | |
| Cancer patient identification | |
| Self-report | 15 (33) |
| Medical record review | 12 (27) |
| Registry | 8 (18) |
| Other | 5 (11) |
| Claims | 5 (11) |
| Cancer stage | |
| Stage I–III/localized regional | 9 (20) |
| Stage IV/distant | 0 (0) |
| Other | 0 (0) |
| All | 22 (49) |
| Not listed | 14 (31) |
| Number of cancer survivors | |
| <100 | 2 (4) |
| 100–999 | 20 (44) |
| 1000–9999 | 19 (42) |
| 10 000+ | 4 (9) |
| Patient age group | |
| <18 | 3 (7) |
| 18–39 | 36 (80) |
| 40–64 | 38 (84) |
| 65+ | 33 (73) |
| Not listed | 2 (4) |
| Cancer site | |
| Other cancer site | 30 (68) |
| Breast | 19 (42) |
| All cancer sites | 16 (36) |
| Colon | 17 (38) |
| Lung | 11 (24) |
| Prostate | 9 (20) |
| Uterine | 5 (11) |
| Ovarian | 4 (9) |
| Financial burden measures | |
| Material measures | |
| Direct costs/out-of-pocket costs | 20 (44) |
| Indirect costs/productivity loss | 18 (40) |
| Medical debt/depletion of assets | 12 (27) |
| Health related spending >20% of income | 4 (9) |
| Decline in financial status | 3 (7) |
| Patient time cost | 3 (7) |
| Bankruptcy | 3 (7) |
| Psychological response measures | |
| Financial distress/worry | 3 (7) |
| Coping behavior measures | |
| Prescription drug management/treatment nonadherence | 7 (16) |
| Composite or summary measures | 13 (29) |
*MEPS = Medical Expenditures Panel Survey; NHIS = National Health Interview Survey; SEER = Surveillance, Epidemiology and End Results program.